All Publications


  • The impact of presentations in scientific conferences: Publication and citation rates in trauma surgery. The journal of trauma and acute care surgery Touponse, G., Bidwell, S., Shank, A., Tai, J., Poe, J., Berg, A., Khan, H., Tian, L., Coimbra, R., Choi, J. 2026

    Abstract

    Understanding the publication rates and citation patterns of conference abstracts is critical for program committees and investigators alike. However, the downstream scholarly outcome of conference abstracts remains poorly characterized. We hypothesized that across contemporary US trauma-related scientific meetings, a substantial proportion of conference abstracts would not progress to peer-reviewed publications, and that publication rates and citation patterns would vary by presentation format and conference.We conducted a cross-sectional study of abstracts presented at four major US trauma surgery conferences from 2017 to 2019. We identified peer-reviewed manuscripts associated with conference abstracts via Google Scholar and PubMed. We collected presentation format, publishing journal, 2024 journal impact factor, and citation count. A cohort of directly submitted peer-reviewed manuscripts was also analyzed. Mixed-effects Poisson regression models assessed the association between presentation and citation counts, adjusting for publication timing.Of 1,157 abstracts, 762 (66%) were published as peer-reviewed manuscripts. Most manuscripts were published in the Journal of Trauma and Acute Care Surgery (JTACS) (55%), with 5 in journals with a higher-impact factor than JTACS. On regression analysis, abstracts presented as oral presentations, and published in journals with an impact factor higher than JTACS, were associated with a greater number of citations. When comparing manuscripts presented as abstracts to directly submitted peer-reviewed manuscripts, abstract presentation was associated with 22% more citations (incidence rate ratio: 1.22; 95% CI [1.16-1.29]; p<0.001).This cross-sectional study of four trauma societies found that approximately a third of presented abstracts did not progress to peer-reviewed publication, with publication rates varying by conference and presentation format. Exploratory analyses found that among those published in JTACS, published manuscripts originating from presented abstracts demonstrated a modestly higher citation count compared with directly submitted manuscripts. Our findings highlight an opportunity to better understand how conference time and investigator effort translate into downstream scholarly output.Prognostic/Epidemiological; Level IV.

    View details for DOI 10.1097/TA.0000000000005188

    View details for PubMedID 42912484

  • Biphasic, time-dependent neutrophil biology in glioblastoma revealed by <i>in vivo</i> survival and flow cytometry with single-cell transcriptomic corroboration Abikenari, M., Choi, J., Liu, J., Sjoholm, A., Nageeb, G., Poe, J., Hwa-Lin Bergsneider, B., Tran, A., Bakalov, D., Medikonda, R., Kim, L., Verma, R., Wu, C., Cho, K., Banu, M., Lim, M. AMER ASSOC CANCER RESEARCH. 2026
  • Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026. Cells Poe, J., Kim, C., Coleman, C., Nguyen, H., Velazhahan, V., Bergsneider, B., Sanker, V., Kim, S., Chen, Y., Abikenari, M., Choi, J., Lim, M. 2026; 15 (6)

    Abstract

    Glioblastoma (GBM) persists as one of the greatest challenges in the treatment of human cancer, despite extensive efforts to leverage the therapeutic potential of immunotherapy. While checkpoint blockade and other forms of immunotherapy have revolutionized the treatment of various cancers, their therapeutic efficacy in GBM has been hindered by the profound immunosuppressive environment, spatial heterogeneity, and dynamic immune metabolic challenges associated with the tumor microenvironment. In this review, we will synthesize recent advances and insights to develop a next-generation framework for GBM immunotherapy based on systems biology approaches to understanding the complex interplay between GBM and the immune system, as opposed to single-axis approaches to immune activation and modulation. We will discuss how the functional competence of the interferon system, myeloid antigen presentation status, T-cell clone status, spatial organization of the immune microenvironment, and resource competition between GBM and the immune system dictate therapeutic responsiveness. Furthermore, the current paper elucidates how recent advances in spatial transcriptomics, single-cell analysis, and high-parameter imaging enable us to understand how immune phenotype status varies across GBM regions and treatment status, and how this information can be used to develop predictive and pharmacodynamic biomarkers of therapeutic efficacy and failure. We will then discuss how these advances form the basis for rational combination approaches to GBM immunotherapy, which involve the integration of checkpoint blockade with metabolic reprogramming, myeloid modulation, and interferon system reactivation, and how artificial intelligence-based analytics and adaptive clinical trial design can guide the development of biomarker-based therapeutic selection approaches.

    View details for DOI 10.3390/cells15060561

    View details for PubMedID 41892350

    View details for PubMedCentralID PMC13025625

  • Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma. Metabolites Abikenari, M., Nageeb, G., Ha, J. H., Sjoholm, M. A., Liu, J., Bergsneider, B., Valenzuela, J., Poe, J., Bog Cho, K., Verma, R., Wu, C., Sanker, V., Medikonda, R., Kim, L. H., Choi, J., Banu, M. A., Lim, M. 2026; 16 (3)

    Abstract

    Glioblastoma (GBM) is a universally fatal cancer for which the standard of care has remained largely unchanged for the last 20 years. Recent work has demonstrated that most therapeutic trials for GBM fail due to complex mechanisms of immunosuppression mediated by both the innate and adaptive immune systems. Various metabolic alterations in the tumor microenvironment help maintain this local and systemic immunosuppression, of which the axis of hypoxia-driven tryptophan degradation has garnered substantial attention over the last decade. This paper synthesizes a much-needed elucidation of the immunometabolic reshaping of glioma, myeloid, endothelial, and lymphoid cell lineages induced by hypoxia. The current paper critically evaluates the role of IDO1/TDO2-mediated breakdown of tryptophan and the consequent accumulation of kynurenine, a metabolite that triggers GCN2- and AHR-mediated CD8+ T-cell exhaustion and supports regulatory T-cell differentiation and expansion. Furthermore, we propose a synthesis of mechanistic evidence that establishes a role for the Trp-GCN2-ATF4-VEGFA axis in hypoxia-induced immunosuppression, supporting that pro-tumoral metabolic dysregulation is directly linked to angiogenesis. In GBM, hypoxia and tryptophan-kynurenine pathway dysregulation operate as an integrated metabolic circuit that drives widespread immunosuppression. These mechanisms can be captured by a metabolic signature shared across nearly every cell type in the GBM microenvironment. Drawing on recent spatial transcriptomic, metabolomic, and pharmacologic studies, we outline how this metabolic axis shapes disease biology and how it can be targeted to restore effective antitumor immunity.

    View details for DOI 10.3390/metabo16030185

    View details for PubMedID 41893336

    View details for PubMedCentralID PMC13028454

  • When Central Tolerance Fails: Thymic Malignancies at the Intersection of Cancer Immunity and Autoimmunity. Cancers Abikenari, M., Choi, J., Enayati, I., Tucker, A., Bhatnagar, K., Chen, Y., Himic, V., Liu, J., Nageeb, G., Poe, J., Ong, S. J., Sanker, V., Diehl, M., Szeifert, V., Terasaki, A., Prolo, L. M., Engleman, E., Okwan-Duodu, D. 2026; 18 (5)

    Abstract

    Thymic malignancies are rare cancers arising from thymic epithelial cells and are characterized by a highly diverse clinical phenotype, substantial histologic and morphologic heterogeneity, and frequent associations with autoimmune syndromes. Although the clinical, immunological, and cytoarchitectural changes associated with thymomas have been increasingly elucidated in the contemporary literature, very few studies have interrogated the direct role of tumor staging and histological grading in shaping autoimmunity burden and infection risk. In this narrative review, we synthesize contemporary clinical, immunological, and morphologic evidence linking thymic architecture and selection defects to the spectrum of paraneoplastic autoimmunity (MG, pure red cell aplasia, Good's syndrome) and to infectious vulnerability. We further appraise emerging therapeutic strategies, including immune checkpoint inhibition and adoptive cellular approaches, through a patient-stratified lens, emphasizing efficacy signals, immune-related adverse events, and practical considerations for selection and monitoring. We conclude by highlighting priorities for future investigation, including refining autoantibody signatures; mapping thymic microenvironments that drive tolerance failure, and prospectively evaluating stratified immunotherapeutic regimens that balance benefit with immune-mediated risk.

    View details for DOI 10.3390/cancers18050747

    View details for PubMedID 41827683